The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
How I would treat patients with R/R DLBCL in 2023 and the future
Featured:
Ulrich Jäger
Grzegorz Nowakowski
Martin Dreyling
Stefano Luminari
Marek Trněný
Gilles Salles
Francesc Bosch
Astrid Pavlovsky
Judith TrotmanDuring the Lymphoma Hub Steering Committee meeting, Marek Trněný chaired a discussion on, How I would treat patients with R/R DLBCL in 2023 and the future.
How I would treat patients with R/R DLBCL in 2023 and the future
This discussion also featured Gilles Salles, Grzegorz Nowakowski, Martin Dreyling, Judith Trotman, Ulrich Jӓger, and Astrid Pavlovsky, Stefano Luminari, and Francesc Bosch. The panel discussed:
- questions and factors considered for subsequent treatment, such as autologous stem cell transplant or CAR T-cell therapy;
- the impact of access to CAR T-cell therapy and when eligible patients can receive treatment after relapse; and
- the importance of time to relapse in deciding treatment.